Research Analysts Issue Forecasts for HRTX Q1 Earnings

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Equities researchers at Northland Capmk issued their Q1 2025 earnings estimates for Heron Therapeutics in a report released on Thursday, February 27th. Northland Capmk analyst C. Byrnes expects that the biotechnology company will earn ($0.01) per share for the quarter. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share. Northland Capmk also issued estimates for Heron Therapeutics’ Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.00 EPS and Q4 2025 earnings at $0.01 EPS.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.05. The firm had revenue of $40.78 million for the quarter, compared to analysts’ expectations of $37.37 million.

HRTX has been the subject of several other research reports. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a report on Friday, February 28th. StockNews.com raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, February 28th.

Heron Therapeutics Price Performance

NASDAQ HRTX opened at $2.55 on Monday. Heron Therapeutics has a 1 year low of $1.04 and a 1 year high of $3.93. The stock has a market capitalization of $387.84 million, a PE ratio of -14.17 and a beta of 1.60. The business’s 50-day moving average is $1.72 and its 200 day moving average is $1.72.

Institutional Trading of Heron Therapeutics

A number of hedge funds have recently modified their holdings of HRTX. Nicolet Advisory Services LLC purchased a new stake in Heron Therapeutics in the fourth quarter worth about $25,000. Argent Advisors Inc. bought a new position in shares of Heron Therapeutics during the fourth quarter valued at $31,000. Focus Partners Wealth purchased a new position in shares of Heron Therapeutics in the 4th quarter worth about $31,000. Y Intercept Hong Kong Ltd purchased a new stake in Heron Therapeutics during the 3rd quarter valued at about $39,000. Finally, Capstone Investment Advisors LLC bought a new stake in Heron Therapeutics during the 3rd quarter valued at about $45,000. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.